Health 89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of… James Pereira Dec 13, 2022 – Data from cohorts 1-6 in the proof-of-concept study showed pegozafermin was generally well tolerated and had… Read More...
Health 89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume James Pereira Nov 15, 2021 New sub-analysis presented at The Liver Meeting® 2021 shows treatment with BIO89-100 reduced spleen volume by an… Read More...
